New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

vTv Therapeutics Inc.

Contributing Author

Recent Articles by vTv Therapeutics Inc.

Mar-16	vTv Therapeutics to Participate in the 38th Annual ROTH Conference VTVT +14.57% GlobeNewswire
Mar-10	vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update VTVT GlobeNewswire
Feb-13	vTv Therapeutics to Participate in Upcoming Investor Conferences VTVT -7.18% GlobeNewswire
Feb-02	vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737 VTVT +8.19% GlobeNewswire
Dec-18	vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health VTVT GlobeNewswire
Nov-06	vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update VTVT +5.07% GlobeNewswire
Oct-09	vTv Therapeutics Announces New Appointments to its Scientific Advisory Board VTVT GlobeNewswire
Sep-15	vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting VTVT GlobeNewswire
Sep-03	UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences VTVT GlobeNewswire
Sep-03	vTv Therapeutics to Participate in Upcoming September Investor Conferences VTVT GlobeNewswire
Sep-02	vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund VTVT +13.30% GlobeNewswire
Aug-12	vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update VTVT -6.35% GlobeNewswire
Aug-11	vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin VTVT +10.52% GlobeNewswire
Aug-07	vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes VTVT GlobeNewswire
Jun-11	vTv Therapeutics to Participate in the H.C. Wainwright "HCW@Home" Series VTVT GlobeNewswire
May-19	vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin VTVT GlobeNewswire
May-15	vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update VTVT -6.16% VTVT +5.16% GlobeNewswire
May-15	vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes VTVT -6.16% VTVT +5.16% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)